Custom folate-modified LNP development for targeted delivery to folate receptor-expressing cells.
Folate-conjugated lipid nanoparticles, also known as folate-LNPs or FA-LNPs, are LNP delivery systems engineered with folic acid, folate derivatives, or folate-bearing lipid conjugates displayed on the particle surface. These ligands can interact with folate receptor-expressing cells and support receptor-mediated internalization in suitable research models. Folate receptor alpha, or FRα, is widely studied in FR-positive tumor cell models, while folate receptor beta, or FRβ, is often associated with activated macrophages, tumor-associated macrophage-like cells, and inflammation-related immune cell models.
Compared with large protein ligands, folate is a small-molecule targeting ligand with defined chemical structure, flexible conjugation routes, and good compatibility with lipid-based nanoparticle engineering. However, successful folate-LNP development is not achieved by simply adding folic acid to an existing LNP. Ligand exposure, PEG shielding, linker length, folate density, ionizable lipid compatibility, payload encapsulation, endosomal release, and receptor-specific validation must be optimized together.
BOC Sciences supports targeted LNP development for folate receptor-oriented delivery projects. Our services cover folate ligand design, folate-lipid conjugate preparation, LNP surface engineering, payload-compatible formulation development, physicochemical characterization, and FR+ cell uptake and functional evaluation. We help build folate-modified LNP systems for the delivery of siRNA, mRNA, circRNA, guide RNA/mRNA combinations, proteins, peptides, small molecules, and other payloads to target folate receptor-expressing cells and tissues, supporting therapeutic research, mechanism studies, imaging, and other diverse applications.
Folate Ligand Linked Lipid Nanoparticle DiagramBOC Sciences provides an integrated folate-LNP development workflow from folate ligand engineering and LNP preparation to surface characterization, receptor-specific uptake evaluation, and payload function analysis.
We design and prepare folate-bearing components according to the target receptor subtype, payload type, formulation route, and expected surface display strategy.
We select folate incorporation methods according to the LNP composition, payload stability, surface ligand density, and preferred process route.
Folate modification can influence LNP self-assembly, payload encapsulation, surface charge, colloidal stability, and cellular delivery. We optimize the folate surface layer and LNP core formulation as one integrated system.
We characterize folate-modified LNP candidates to confirm particle quality, folate display, payload retention, and formulation comparability across screening groups.
We design evaluation studies to help distinguish folate receptor-related uptake from general nanoparticle internalization or macrophage-associated phagocytosis.
BOC Sciences supports process optimization for folate-LNP preparation, focusing on preparation consistency, ligand incorporation efficiency, payload retention, and reproducible particle attributes.
BOC Sciences develops folate-modified LNPs using structure-guided ligand engineering and formulation-compatible surface modification strategies. Depending on the project goal, we can help select monovalent folate, multivalent folate clusters, folate analogs, PEG-bridged folate lipids, pH-responsive linkers, or covalent coupling strategies.
Folate ligands can be designed in different structural formats. BOC Sciences helps clients select a suitable folate ligand based on receptor type, target cell model, payload type, surface exposure needs, and formulation stability.
| Folate Ligand Option | What It Means | Why Use It | Typical Research Uses |
|---|---|---|---|
| Monovalent Folate | One folate molecule is connected to one lipid anchor, usually through a PEG linker. | Simple structure, easy to introduce into LNPs, and suitable for initial folate receptor-targeting studies. | Basic FR+ cell uptake studies, early feasibility screening, and comparison with unmodified LNPs. |
| Divalent Folate, FA2 | Two folate molecules are displayed on one branched linker or dual-arm folate-lipid structure. | Provides stronger receptor interaction than single folate display in some FR-rich cell models. | FRα+ tumor cell uptake studies, receptor-density comparison, and improved targeting screening. |
| Multivalent Folate, FA4-FA8 | Multiple folate molecules are arranged on a dendritic, branched, or polymer-like scaffold. | Increases the chance of receptor binding through multivalent interaction, especially in high-FR expression models. | High-FR tumor models, tumor spheroid uptake studies, and intensive ligand-density optimization. |
| Folate-PEG-Lipid Ligands | Folate is connected to a lipid anchor through a PEG spacer, such as FA-PEG2000-DSPE or short-chain FA-PEG-lipid. | PEG works as a flexible arm that extends folate from the LNP surface and helps the receptor recognize it. | Most folate-LNP surface modification projects, including siRNA, mRNA, small molecule, and imaging payload delivery. |
| Folate-Cholesterol Ligands | Folate is connected to cholesterol or a cholesterol-like lipid anchor for insertion into the LNP lipid layer. | Useful for mild post-insertion or rapid surface modification of preformed LNPs. | Fast feasibility testing, post-insertion screening, and comparison with phospholipid-anchored folate ligands. |
| Folate Analog-Inspired Ligands | Folate-related structures, such as 5-MTHF-inspired or antifolate-inspired motifs, are used for comparative ligand design. | Helps researchers compare whether alternative folate-related ligands offer better receptor interaction or payload compatibility. | Ligand structure comparison, receptor-specific uptake studies, and custom folate-LNP feasibility projects. |
| pH-Responsive Folate Ligands | Folate is connected through an acid-sensitive linker, such as hydrazone or acylhydrazone linkage. | Designed to remain stable near neutral conditions and respond after entry into acidic intracellular compartments. | Endosome-related release studies, intracellular trafficking research, and responsive folate-LNP formulation screening. |
We develop folate coupling methods according to payload sensitivity, expected folate orientation, reaction compatibility, and the required level of surface control.
| Coupling Strategy | Service Subtype | Chemical Principle | Suitable Use Cases |
|---|---|---|---|
| Lipid Anchoring | Folate-cholesterol insertion | Folate-cholesterol is inserted into the LNP lipid layer through hydrophobic interaction. | Rapid and mild modification for early feasibility screening. |
| Folate-DSPE/DSPC co-assembly | Folate-phospholipids participate in LNP assembly as structural lipid components. | Stable folate display and more controllable orientation during formulation development. | |
| PEG Bridging | FA-PEG2000-DSPE post-insertion | PEG spacer provides flexibility and spatial separation from the LNP surface. | Common route for balancing particle stability and folate receptor accessibility. |
| FA-PEG54-DSPE short-chain bridging | Short PEG reduces excessive shielding and keeps folate closer to the particle surface. | Useful for high-density folate display and tumor penetration-oriented formulation studies. | |
| Covalent Coupling | Thiol-maleimide coupling | Folate-thiol reacts with Mal-PEG-lipid displayed on the LNP surface. | Selective surface conjugation when reaction pH and ligand input are controlled. |
| DBCO-azide copper-free click chemistry | Folate-azide reacts with DBCO-PEG-lipid on the LNP surface. | Bioorthogonal conjugation for surface-modified LNP screening. | |
| Amide bond formation | Folate carboxyl groups are coupled with amine-functionalized LNP surfaces. | Classical conjugation route requiring careful control of crosslinking and surface charge. | |
| Non-Covalent Affinity Assembly | Biotin-streptavidin bridging | Modular assembly based on high-affinity biotin-streptavidin interaction. | Rapid folate display screening and proof-of-concept receptor uptake studies. |
Develop folate-modified LNPs with optimized folate exposure, payload loading, particle quality, FRα/FRβ-oriented uptake evaluation, and functional delivery readouts.
Folate-modified LNPs use a small vitamin-derived ligand to guide lipid nanoparticles toward cells that overexpress folate receptors. This approach combines deep tissue penetration with payload versatility, offering a practical path for targeted delivery of RNA therapeutics, small molecules, and imaging agents.
One Ligand, Two Receptor Pathways
Folate receptors come in two main forms. FRα is highly expressed on ovarian, lung, and breast cancer cells, making it a validated target for solid tumor delivery. FRβ appears on activated macrophages and tumor-associated macrophages (TAMs), opening routes for inflammation and immuno-oncology applications. With folate engineering, you can explore both pathways from a single platform—adjusting density and formulation to favor tumor cell uptake or macrophage engagement without redesigning the ligand from scratch.
Small Size, Deep Tumor Reach
At 441 Da, folic acid is roughly 300 times smaller than a typical antibody. This compact size matters in dense tumor tissue, where large ligands are physically blocked from reaching cells deep in the mass. Folate also binds its receptor with sub-nanomolar affinity—among the tightest small-molecule interactions known—so even low surface density achieves meaningful uptake. The chemistry is fully synthetic, giving you batch-to-batch consistency and straightforward quality control by HPLC and mass spectrometry, without the cost and variability of biological production.
Same Surface, Different Payloads
Folate modification does not lock you into one cargo type. The same engineering strategy works for siRNA, mRNA, circRNA, proteins, peptides, small molecules, and imaging probes. This means you can pivot from an RNA program to a small-molecule or combination therapy without rebuilding your delivery platform from the ground up—saving development time and preserving validated analytical methods across projects.
Repeat Dosing Without Immunogenicity Risk
Folic acid is an endogenous vitamin with established metabolic pathways. Unlike protein-based targeting ligands, it carries no risk of triggering anti-drug antibodies (ADA), which can neutralize efficacy and complicate regulatory filings. This makes folate-LNPs suitable for chronic dosing regimens and combination therapies where repeated administration is essential for clinical response.
BOC Sciences develops folate-modified LNPs for different payload types used in folate receptor-targeted delivery research. We help match each payload with suitable folate surface design, LNP formulation strategy, and FR+ cell evaluation model.
| Payload Type | Supported Applications | Request Information |
|---|---|---|
| Folate-LNP Development for siRNA | Used for gene silencing in FRα+ tumor cell models, FRβ+ activated macrophage models, and inflammation-related pathway studies. Typical applications include oncogene knockdown, macrophage pathway modulation, cytokine signal reduction, and target validation in receptor-positive cell systems. | Inquiry |
| Folate-LNP Development for mRNA | Applied to protein expression, immune-modulating factor delivery, tumor cell reprogramming research, macrophage phenotype regulation, and antigen-expression studies in folate receptor-expressing cells. Folate modification helps direct mRNA-loaded LNPs toward selected FR+ cell populations. | Inquiry |
| Folate-LNP Development for Reporter RNA | Suitable for evaluating folate receptor-targeted delivery efficiency, intracellular expression, formulation comparison, and ligand density screening. Reporter RNA systems are often used to compare FRα+/FR-low tumor cells, activated/non-activated macrophages, and folate competition groups. | Inquiry |
| Folate-LNP Development for circRNA | Used for sustained expression studies, circular RNA delivery evaluation, and receptor-oriented RNA delivery research. Folate-modified circRNA LNPs can be applied in FR+ tumor cell models, macrophage-related models, and long-expression reporter studies. | Inquiry |
| Folate-LNP Development for Self-Amplifying RNA | Designed for strong and extended RNA expression studies in folate receptor-expressing cells. Typical uses include antigen-expression research, immune-response model studies, and comparative evaluation of folate ligand density on RNA expression output. | Inquiry |
| Folate-LNP Development for gRNA | Used for co-delivery of guide RNA and mRNA components to FR+ cells. These systems support receptor-targeted gene editing research, target gene disruption studies, and comparison of folate-modified LNPs with non-targeted LNP controls. | Inquiry |
| Folate-LNP Development for Protein | Applied to intracellular protein delivery, enzyme delivery, antigen delivery, binding protein delivery, and functional protein transport into folate receptor-expressing cells. Folate modification can help improve cell-selective uptake in FR-rich tumor or immune-cell models. | Inquiry |
| Folate-LNP Development for Peptide | Used for delivery of functional peptides, antigenic peptides, cell-penetrating peptides, immune-modulating peptides, and receptor-related peptide payloads. Folate-LNPs can support peptide uptake studies in FRα+ tumor cells and FRβ+ macrophage-related models. | Inquiry |
| Folate-LNP Development for Small Molecule | Suitable for hydrophobic drugs, amphiphilic compounds, ionizable molecules, kinase pathway modulators, antifolate-inspired payloads, and tumor microenvironment-modulating small molecules. Folate modification supports targeted delivery studies in FR-expressing tumor and macrophage models. | Inquiry |
| Folate-LNP Development for Imaging Probe | Used for fluorescent tracking, receptor-mediated uptake visualization, intracellular localization, tumor spheroid penetration, tissue distribution trend studies, and folate receptor-targeting mechanism evaluation. These systems are useful for connecting formulation design with visible delivery behavior. | Inquiry |
| Folate-LNP Development for Dual-Payload | Designed for co-delivery of RNA and small molecules, RNA and imaging probes, protein and adjuvant-like molecules, or other combination payloads. These systems support mechanism studies, combination delivery research, and multi-readout formulation evaluation in FR+ cell models. | Inquiry |
| Folate-LNP Development for Custom Payload | Developed for unusual payloads, exploratory delivery systems, early feasibility studies, and project-specific folate receptor-targeted applications. BOC Sciences evaluates payload compatibility, folate surface strategy, particle behavior, and receptor-positive cell delivery performance. | Inquiry |
Folate-LNP development often faces bottlenecks when folate display, LNP core formulation, payload loading, receptor biology, and functional readouts are not evaluated together. BOC Sciences helps clients identify the real source of performance loss.
✔ Weak FR+ Cell Uptake Improvement
A folate-LNP may show limited uptake improvement if the folate ligand is masked by PEG, displayed at a poor density, or placed too close to the LNP surface. We optimize folate-lipid structure, PEG spacer length, ligand density, and PEG-lipid ratio through LNP PEG-lipid optimization services.
✔ Particle Size Increase After Folate Modification
Excessive folate-lipid incorporation can disturb LNP self-assembly and lead to larger particles or broader PDI. We rebalance helper lipids, cholesterol, ionizable lipid systems, PEG-lipids, and folate-bearing lipids to restore particle uniformity.
✔ Reduced Payload Encapsulation
Folate-bearing lipids may alter the self-assembly environment required for RNA or drug loading. We optimize lipid composition, aqueous phase conditions, payload input, and processing parameters for nucleic acids encapsulation in LNPs and other payload formats.
✔ Unclear Folate Receptor Contribution
FR+ cells can internalize nanoparticles through multiple pathways. We design FR-high and FR-low cell comparisons, free folic acid competition, unmodified controls, ligand-density variants, and receptor-related readouts to clarify the targeting contribution.
✔ High Uptake but Weak Payload Function
Strong uptake does not always lead to strong mRNA expression, siRNA knockdown, or small molecule activity. We evaluate RNA integrity, intracellular localization, endosomal escape, and functional response with LNP endosomal escape evaluation when needed.
✔ Folate Density and Stability Conflict
High folate density may improve receptor interaction in some models, but excessive surface modification can increase aggregation or reduce storage stability. We select candidates by combining particle data, folate display data, payload retention data, and cell-based delivery results.
BOC Sciences helps research teams troubleshoot folate ligand exposure, payload encapsulation, particle instability, FR-specific uptake, endosomal escape, and functional delivery readouts.
We begin by reviewing your payload type, target receptor subtype, target cell model, preferred readout, expected LNP attributes, and project objective. We clarify whether your study focuses on FRα+ tumor cells, FRβ+ macrophage-like cells, kidney-related FR+ cells, trophoblast-related models, or other folate receptor-expressing systems.
BOC Sciences designs a folate surface strategy that matches your target receptor and payload. The design may include folate ligand type, PEG spacer length, lipid anchor, folate density range, pH-responsive linker option, and coupling route. We also support nanoparticle surface functionalization services for surface-engineered delivery systems.
We prepare folate-LNP candidates using co-assembly, post-insertion, or covalent coupling strategies. During LNP process optimization, we adjust lipid composition, payload loading, mixing conditions, buffer exchange, folate density, and particle stability. Matched unmodified LNPs and ligand-free controls can also be prepared for comparison.
Each folate-LNP candidate is evaluated for particle size, PDI, zeta potential, payload loading, folate density, and formulation integrity. We can also support nanoparticle cellular uptake testing, intracellular localization, reporter expression, gene silencing, release behavior, and distribution-related readouts in suitable research models.
Folate-modified LNPs leverage FRα on tumor cells and FRβ on activated macrophages to deliver payloads with receptor-level precision. This dual-targeting design spans oncology, immuno-oncology, inflammatory disease, and organ-specific gene therapy.
Challenge: A research team was developing a folate-modified LNP to deliver siRNA into FRα+ ovarian tumor cell models. Their first formulation showed acceptable siRNA encapsulation, but uptake improvement over the unmodified LNP was inconsistent. The client needed to determine whether the issue came from folate masking, insufficient ligand density, or weak intracellular release after uptake.
Diagnosis: BOC Sciences reviewed the original formulation and found that the PEG-lipid level likely reduced folate receptor accessibility. The folate ligand was displayed through a long spacer, but the folate-bearing lipid input was too low to generate a clear difference between FRα+ and FRα-low control cells. The formulation also showed moderate endosomal retention after uptake.
Solution: BOC Sciences prepared a screening panel using FA-PEG2000-DSPE and a shorter folate-PEG-lipid design. We compared three folate densities, two PEG-lipid ratios, and two ionizable lipid balances. Candidate LNPs were evaluated by particle size, PDI, siRNA encapsulation, folate display analysis, FRα+/FRα-low uptake comparison, free folic acid competition, intracellular localization, and target gene knockdown.
Result: The selected folate-LNP maintained an average particle size of about 108 nm with a PDI below 0.20. siRNA encapsulation remained above 82%. Compared with the unmodified LNP, the optimized formulation showed about 2.3-fold higher uptake in the FRα+ cell model and approximately 60% target gene knockdown under the selected in vitro condition. The client obtained a clearer formulation direction and receptor-specific control design for follow-up studies.
Challenge: A biotechnology group wanted to deliver an immune-modulating mRNA payload into FRβ+ macrophage-like cells. Their monovalent folate-LNP showed measurable uptake, but the mRNA expression signal was weak and the uptake difference between activated and non-activated macrophage models was not convincing.
Diagnosis: BOC Sciences found two main issues. First, monovalent folate display was not strong enough for the selected macrophage model. Second, the formulation produced high particle uptake but insufficient cytosolic delivery, suggesting that endosomal release and ionizable lipid balance needed further optimization.
Solution: We designed a multivalent folate ligand panel, including FA2 and FA4 display formats, and compared them with the original monovalent folate-LNP. The screening included ligand density, PEG spacer length, ionizable lipid ratio, and buffer exchange condition. Candidate LNPs were evaluated by mRNA integrity, particle attributes, folate display, activated macrophage uptake, free folate competition, intracellular localization, and reporter expression.
Result: The optimized FA4-LNP maintained an average particle size of about 118 nm and mRNA encapsulation above 76%. Activated macrophage uptake increased by about 1.9-fold compared with the monovalent folate-LNP, while reporter expression improved by about 2.6-fold under the selected in vitro condition. The client received a data-supported ligand architecture and formulation strategy for FRβ-oriented macrophage delivery research.
Full-Workflow Folate-LNP DevelopmentWe handle the entire process: folate ligand design, folate-lipid synthesis, LNP formulation, payload loading, and FR⁺ cell testing. Clients move from feasibility to optimized delivery systems without gaps between steps.
Advanced LNP ManufacturingWe use microfluidic mixing, post-insertion, and systematic screening to produce folate-LNPs with consistent properties batch after batch.
Diverse Lipid and Ligand LibraryWe supply ionizable lipids, PEG-lipids, folate-PEG-lipids, folate-cholesterol, multivalent clusters, and pH-responsive variants—so you can screen the right match for your target cells and payload.
Precise FRα/FRβ Targeting ValidationUptake alone does not prove targeting. We run FR⁺ vs FR⁻ cell comparisons, free folate competition assays, and unmodified LNP controls to confirm that folate modification—not particle size or charge—drives the delivery.
Payload-Tailored Formulation OptimizationWe optimize each system for its specific cargo, linking formulation choices to functional results like gene silencing, expression levels, or imaging signal.
Folate-modified LNP development is mainly used to build lipid nanoparticle systems with improved delivery toward folate receptor-expressing cells. These systems are frequently explored for targeted delivery of siRNA, mRNA, circRNA, small molecules, proteins, peptides, and imaging payloads. By displaying folate ligands on the LNP surface, the formulation may enhance receptor-mediated cellular uptake in FRα- or FRβ-related cell models. For drug discovery researchers, the key goal is not only higher uptake, but also better payload function after internalization. BOC Sciences supports folate ligand selection, FA-lipid incorporation, formulation screening, particle characterization, and cell-based evaluation to help clients identify more suitable folate-LNP candidates.
Folate-LNPs target folate receptors by presenting folic acid or folate-derived ligands on the nanoparticle surface. When the ligand is sufficiently exposed, the LNP can interact with folate receptors on target cells and enter the cell through receptor-mediated endocytosis. However, successful targeting depends on more than simply adding folate to the formulation. PEG linker length, ligand density, lipid anchor structure, particle size, surface charge, and protein adsorption can all influence receptor accessibility. If folate is hidden by a dense PEG layer, uptake may be weak. If folate density is too high, particle aggregation or non-specific interaction may increase. Therefore, folate-LNP development requires coordinated optimization of surface engineering and core formulation.
Folate-modified LNPs can be designed for a broad range of payloads, including siRNA, mRNA, reporter RNA, circRNA, gRNA/mRNA combinations, small molecules, proteins, peptides, and fluorescent imaging probes. Each payload type requires a different formulation strategy. RNA payloads usually require strong encapsulation, RNA integrity protection, endosomal escape, and functional expression or knockdown evaluation. Small molecule payloads require attention to drug-lipid compatibility, leakage control, and release behavior. Imaging payloads require stable signal retention and clear localization readouts. BOC Sciences develops folate-LNP systems by matching the payload properties with ionizable lipids, helper lipids, cholesterol, PEG-lipids, and FA-lipid components to support both particle quality and targeted delivery performance.
Folate ligand density is one of the most important variables in folate-modified LNP development. A low folate density may not provide enough receptor interaction, while excessive folate display may disturb particle assembly, increase particle size, broaden PDI, or introduce non-specific binding. A practical optimization strategy is to prepare low-, medium-, and high-density FA-lipid formulations and evaluate them side by side. Key readouts may include particle size, PDI, zeta potential, payload loading, folate surface exposure, uptake in folate receptor-positive cells, background uptake in low-expression cells, and functional payload activity. The best candidate is not always the one with the highest uptake; it should show balanced particle stability, receptor-related selectivity, and meaningful payload performance.
Folate-LNP targeting performance should be validated with a clear control design rather than relying only on fluorescence intensity. Useful comparisons may include unmodified LNPs, different folate ligand densities, folate receptor-positive and low-expression cell models, free folate competition groups, and matched payload activity assays. For mRNA-loaded folate-LNPs, reporter protein expression can help evaluate functional delivery. For siRNA-loaded folate-LNPs, target gene knockdown can show whether uptake leads to useful intracellular activity. Flow cytometry, confocal imaging, intracellular localization analysis, and in vitro functional assays can be combined to clarify delivery behavior. BOC Sciences helps clients design targeting evaluation workflows that distinguish true folate receptor-related enhancement from general nanoparticle uptake.
